Corbus Pharmaceuticals
CRBP
63 hedge funds and large institutions have $1.32M invested in Corbus Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 11 increasing their positions, 14 reducing their positions, and 10 closing their positions.
275% more call options, than puts
Call options by funds: $30K | Put options by funds: $8K
10% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 10
0.31% less ownership
Funds ownership: 0.62% → 0.32% (-0.31%)
2% less funds holding
Funds holding: 64 → 63 (-1)
21% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 14
66% less capital invested
Capital invested by funds: $3.86M → $1.32M (-$2.54M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
+$57.5K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$24.9K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$10.8K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$8.23K |
| 5 |
SF
Synovus Financial
Columbus,
Georgia
|
+$6.41K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Knoll Capital Management
Miami,
Florida
|
-$833K |
| 2 |
EMG
ETF Managers Group
Summit,
New Jersey
|
-$777K |
| 3 |
PA
Pinnacle Associates
New York
|
-$104K |
| 4 |
Renaissance Technologies
New York
|
-$88.2K |
| 5 |
Mirae Asset Global Investments
Seoul,
South Korea
|
-$66K |
CRBP Hedge Fund Activity: Q4 2022 in Review
63 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Corbus Pharmaceuticals (CRBP) for Q4 2022, worth a combined $1.32M — down 66% from $3.86M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new CRBP positions and 10 closed out — a net gain of 1 holder — while 11 added to existing stakes and 14 trimmed.
The largest buyer was Two Sigma Investments, adding an estimated $57.5K. The largest seller was Knoll Capital Management, exiting entirely with an estimated $833K sold.
- 63 institutional investors held Corbus Pharmaceuticals (CRBP) as of Q4 2022, down from 64 in Q3 2022.
- Funds reported $1.32M of Corbus Pharmaceuticals stock for Q4 2022, down 66% quarter-over-quarter.
- 11 funds opened new Corbus Pharmaceuticals positions in Q4 2022 and 10 closed out, a net change of +1 holder.
- The largest Corbus Pharmaceuticals buyer in Q4 2022 was Two Sigma Investments, an estimated $57.5K added.
- The largest Corbus Pharmaceuticals seller in Q4 2022 was Knoll Capital Management, an estimated $833K sold.
Based on aggregated 13F filings for Q4 2022.